In mice, a therapy based on editing regulatory T-cells can suppress an immune reaction against gluten, according to a study in Science Translational Medicine. Studies in animals with coeliac disease would be needed to assess the efficacy of this cell therapy in restoring gluten tolerance, the authors say.
An international team has found that aspirin is capable of reducing the appearance of metastasis in mice, by enabling the activation of T lymphocytes capable of recognising tumour cells. The research showed that several different mouse cancer models — including breast cancer, colon cancer and melanoma — treated with aspirin showed a lower rate of metastasis in other organs, such as the lungs and liver, compared to untreated mice. According to the authors, who publish the results in the journal Nature, ‘the finding paves the way for the use of more effective anti-metastatic immunotherapies’.
A team of US researchers has followed some patients treated with CAR-T therapies in a small clinical trial conducted between 2004 and 2009 to treat children with neuroblastoma, a nerve cell tumor that can have a poor prognosis. At least one of them, a woman who was treated with CAR-T as a child, remains in remission 18 years later, the longest duration of such therapy described to date. The results are published in the journal Nature Medicine.
CAR-T cell-based treatments have been successful against some blood tumours, but are much less effective for solid tumours. A phase 1 clinical trial has tested their use in 11 children and young adults with diffuse midline glioma, a tumour of the nervous system that is considered incurable. The results, published in the journal Nature, indicate that the treatment improved functional status in nine of the 11 patients. One of the four who showed a strong response is still healthy four years later.
The regulatory agencies for medicines in the United States and Europe have issued statements informing about a possible risk of developing certain types of tumors following CAR-T cell immunotherapy treatment. What do we know so far? What is the real risk? Does the benefit-risk balance still hold? Has anything changed after these alerts? We answer these questions with expert opinions and the data currently available.
Cancer immunotherapy, and in particular the so-called checkpoint inhibitors, have improved the prognosis of several types of tumours. However, they are not effective in everyone. Two early-stage clinical trials have tested the addition of a type of immunomodulator to this therapy in patients with lung cancer and Hodgkin's lymphoma, with apparent good results. The results are published in the journal Science.
CAR-T cell therapies may, in some cases, produce tumours secondary to treatment. A few months ago, the US Food and Drug Administration (FDA) said it was assessing this risk. Now, a study conducted at Stanford University Medical Center (USA) has tracked 724 patients who received this type of treatment since 2016. Of these, 14 developed another blood tumour, but only one was a T-cell lymphoma that could be a direct consequence of the therapy. Further analysis ruled out this link. The results are published in the journal NEJM.
A multidisciplinary study involving several Spanish research groups has preclinically tested a new type of immunotherapy for multiple myeloma. Instead of modifying T cells to attack the tumour directly, as CAR-T cells do, they have managed to make them secrete bispecific antibodies, which bind to the tumour on one side and to other T cells on the other, attracting them to the tumour. According to the authors, this cell therapy was more effective than traditional CAR-Ts and could generate less resistance. The results are published in the journal Science Translational Medicine.
The US Food and Drug Administration (FDA) has issued a statement reporting that it has received reports of T-cell tumours in patients who received various CAR-T cell treatments. As quoted in the statement, "although the overall benefits of these products continue to outweigh their potential risks for their approved uses, FDA is investigating the identified risk of T cell malignancy with serious outcomes, including hospitalization and death, and is evaluating the need for regulatory action".
News of cancer vaccines proliferate in the media, yet only one such vaccine has been approved - against metastatic prostate cancer - and is no longer in use. However, only one as such has been approved - against metastatic prostate cancer - and it is no longer in use. Are the attention and hopes justified? What do they consist of and how are they similar to traditional ones? Are they preventive or therapeutic? Can they be universal or will they be extremely personalised? How much will they cost? This is what we know today.